TOward the Lowest Effective DOse of Abatacept or Tocilizumab
Status:
Completed
Trial end date:
2019-11-08
Target enrollment:
Participant gender:
Summary
Ever since the biotherapy agents have entered the market, the recommended therapeutic
objective in Rheumatoid arthritis, has been remission. Once obtained, it is advised to try to
reduce or cease these biotherapy agents, for which, their efficacy is counterbalanced to
their tolerance in the medium and long term as well as their high price. Nevertheless, we do
not dispose considerable data on the risks of relapse or structural progression during such a
step down strategy. A few studies on anti-TNF agents have shown the possibility of such
therapy reduction. A national study, " STRASS ", coordinated by Bruno FAUTREL, has evaluated
the possibility of spacing or even stopping the injections of anti-TNF(s). To date, no data
concerning Abatacept or Tocilizumab has been published.
As the expected result, this study is aimed to test the feasibility of a step down strategy
on 2 biological agents, Abatacept and Tocilizumab, in RA patients in remission.